Fennec Narrows Q3 Loss on Strong PEDMARK Sales, Cash Declines

TL;DR

**FENC is burning cash, but PEDMARK sales are picking up, making it a speculative buy on growth potential.**

AI Summary

FENNEC PHARMACEUTICALS INC. reported a net loss of $638 thousand for the three months ended September 30, 2025, a significant improvement from the $5,735 thousand net loss in the same period of 2024. For the nine months ended September 30, 2025, the company posted a net loss of $4,954 thousand, contrasting sharply with a net income of $1,549 thousand in the prior year, primarily due to the absence of a $17,958 thousand licensing revenue recognized in 2024. PEDMARK product sales, net, increased substantially to $12,462 thousand for the three months ended September 30, 2025, up from $6,974 thousand in 2024, and to $30,865 thousand for the nine months, compared to $21,655 thousand in 2024. Operating expenses for the nine months decreased to $34,593 thousand from $36,111 thousand, driven by lower selling and marketing expenses. The company's cash and cash equivalents decreased from $26,634 thousand at December 31, 2024, to $21,947 thousand at September 30, 2025, with net cash used in operating activities totaling $6,511 thousand for the nine-month period. Despite the net loss, the company believes its current funds, including a $43,000 thousand upfront payment from Norgine, are sufficient for planned activities for at least the next twelve months.

Why It Matters

For investors, Fennec's improved Q3 net loss and robust PEDMARK sales growth are positive signs, indicating increasing market penetration for its sole approved product. However, the overall nine-month net loss and negative operating cash flow highlight ongoing profitability challenges and reliance on the Norgine licensing deal's upfront payment for liquidity. Employees and customers benefit from the continued commercialization of PEDMARK, a critical treatment for pediatric cancer patients. In the competitive landscape of specialized pharmaceuticals, Fennec's ability to grow PEDMARK sales against a backdrop of declining licensing revenue is crucial for long-term viability and could influence its valuation relative to peers.

Risk Assessment

Risk Level: medium — The company reported a net loss of $4,954 thousand and negative cash flows from operating activities of $6,511 thousand for the nine months ended September 30, 2025. While the company states it has sufficient funding for the next twelve months, this relies heavily on the $43,000 thousand upfront payment from Norgine, indicating a dependence on external financing or significant future revenue growth to sustain operations.

Analyst Insight

Investors should monitor Fennec's PEDMARK sales trajectory closely and assess the company's ability to achieve profitability and positive operating cash flow in future quarters. Consider the long-term implications of the Norgine licensing agreement's milestone payments and royalties as key drivers for future revenue, but be aware of the current cash burn.

Financial Highlights

debt To Equity

N/A

revenue

$30,865,000

operating Margin

-11.9%

total Assets

$49,261,000

total Debt

$18,206,000

net Income

-$4,954,000

eps

N/A

gross Margin

N/A

cash Position

$21,947,000

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $12.46M — PEDMARK product sales, net (Q3 2025) (Increased from $6.97M in Q3 2024, showing strong product growth.)
• $30.87M — PEDMARK product sales, net (9M 2025) (Increased from $21.66M in 9M 2024, indicating consistent sales growth.)
• $(638)K — Net loss (Q3 2025) (Improved from $(5.74)M in Q3 2024, narrowing losses.)
• $(4.95)M — Net loss (9M 2025) (Compared to $1.55M net income in 9M 2024, primarily due to absence of licensing revenue.)
• $(6.51)M — Net cash used in operating activities (9M 2025) (Represents negative cash flow from core operations, a concern for liquidity.)
• $21.95M — Cash and cash equivalents (Sept 30, 2025) (Decreased from $26.63M at Dec 31, 2024, reflecting cash burn.)
• $43.00M — Upfront payment from Norgine (Key source of liquidity, providing funding for at least the next twelve months.)
• $224.64M — Accumulated deficit (Sept 30, 2025) (Indicates historical losses and ongoing challenge to achieve sustained profitability.)
• 28,116,829 — Common shares outstanding (Nov 10, 2025) (Reflects share count for per share calculations and market capitalization.)

Key Players & Entities

• FENNEC PHARMACEUTICALS INC. (company) — Registrant
• PEDMARK (company) — Approved product for ototoxicity
• Norgine Pharma UK Limited (company) — Exclusive licensing agreement partner
• Petrichor Opportunities Fund I LP (company) — Senior secured floating rate convertible notes holder
• FDA (regulator) — U.S. Federal Drug Administration
• EMA (regulator) — European Medicines Agency
• Nasdaq Capital Market (market) — Exchange where common shares are traded
• $43,000 (dollar_amount) — Upfront payment from Norgine
• $230,000 (dollar_amount) — Potential future royalties and milestone payments from Norgine
• $19,477 (dollar_amount) — Outstanding Second Closing Notes principal amount as of September 30, 2025

FAQ

Risk Factors

• Sustained Operating Losses and Accumulated Deficit [high — financial]: The company reported a net loss of $638,000 for Q3 2025 and $4,954,000 for the nine months ended September 30, 2025. The accumulated deficit stands at $224,636,000 as of September 30, 2025, indicating a history of unprofitability and a need for continued funding.
• Declining Cash Position [medium — financial]: Cash and cash equivalents decreased from $26,634,000 at December 31, 2024, to $21,947,000 at September 30, 2025. Net cash used in operating activities was $6,511,000 for the nine months ended September 30, 2025, highlighting ongoing cash burn.
• Dependence on PEDMARK Sales Growth [medium — operational]: While PEDMARK product sales have shown strong growth, increasing by 78.7% in Q3 2025 and 42.5% year-to-date, the company's financial health is heavily reliant on the continued success and expansion of this single product line.
• Long-Term Debt Obligations [medium — financial]: The company has total long-term liabilities of $43,938,000, including a term loan of $18,206,000 and a significant contract liability of $24,561,000. Servicing this debt while operating at a loss presents a financial challenge.
• Regulatory Compliance for Pharmaceutical Products [high — regulatory]: As a pharmaceutical company, Fennec is subject to stringent regulatory oversight from bodies like the FDA. Any adverse regulatory actions, delays in approvals, or changes in regulations could significantly impact product sales and future development.

Industry Context

Fennec Pharmaceuticals operates in the highly competitive and regulated pharmaceutical industry, focusing on orphan drugs. The market for rare disease treatments is growing, driven by unmet medical needs and advancements in biotechnology. However, companies in this space face significant R&D costs, lengthy approval processes, and pricing pressures from payers and competitors.

Regulatory Implications

As a pharmaceutical company, Fennec is subject to rigorous FDA regulations for product approval, manufacturing, and marketing. Any delays in regulatory processes, post-market surveillance issues, or changes in regulatory requirements could materially impact the company's ability to generate revenue and achieve profitability.

What Investors Should Do

1. Monitor PEDMARK sales trajectory and market penetration.
2. Assess cash burn rate and runway.
3. Evaluate the impact of the absence of licensing revenue.
4. Scrutinize operating expense management.

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the latest financial results, showing improved quarterly net loss but a year-to-date net loss due to absence of prior year licensing revenue.
• 2025-12-31: End of Fiscal Year 2024 — Prior period balance sheet date, used for comparison of cash and cash equivalents and other balance sheet items.
• 2024-09-30: End of Third Quarter 2024 — Prior year comparable period for the three and nine months ended statements of operations, highlighting a significant net loss compared to the current period's improved quarterly loss.

Glossary

PEDMARK product sales, net

Revenue generated from the sale of the company's product, PEDMARK, after deducting any returns, allowances, or discounts. (This is the primary revenue driver for Fennec Pharmaceuticals, and its growth is critical to the company's financial performance.)

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company's history of losses and its ongoing challenge to achieve sustained profitability.)

Cash and cash equivalents

Highly liquid short-term investments that are readily convertible to known amounts of cash and which are so near to their maturity that they present an insignificant risk of changes in value. (Represents the company's immediate liquidity and its ability to fund ongoing operations and obligations.)

Net cash used in operating activities

The amount of cash consumed by the company's core business operations during a specific period. (A negative value indicates that the company's operations are not generating enough cash to cover their expenses, requiring external funding or use of existing cash reserves.)

Contract liability - long-term

Obligations to transfer goods or services to a customer in the future for which the company has received consideration from the customer. (Represents future revenue that has been recognized in cash but not yet earned, impacting future revenue recognition and cash flows.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Fennec Pharmaceuticals saw a significant decrease in total revenue from $39,613,000 to $30,865,000, primarily due to the absence of $17,958,000 in licensing revenue recognized in 2024. However, PEDMARK product sales, net, showed robust growth, increasing by 42.5% to $30,865,000. Operating expenses for the nine months decreased slightly to $34,593,000 from $36,111,000, driven by lower selling and marketing costs. The company's net loss for the nine months widened to $4,954,000 from a net income of $1,549,000 in the prior year, reflecting the impact of the lost licensing revenue.

Filing Documents

• fencf-20250930x10q.htm (10-Q) — 1593KB
• fencf-20250930xex31d1.htm (EX-31.1) — 14KB
• fencf-20250930xex31d2.htm (EX-31.2) — 18KB
• fencf-20250930xex32d1.htm (EX-32.1) — 9KB
• fencf-20250930xex99d1.htm (EX-99.1) — 200KB
• fencf-20250930xex99d1001.jpg (GRAPHIC) — 3KB
• 0001104659-25-111260.txt ( ) — 7197KB
• fencf-20250930.xsd (EX-101.SCH) — 49KB
• fencf-20250930_cal.xml (EX-101.CAL) — 38KB
• fencf-20250930_def.xml (EX-101.DEF) — 194KB
• fencf-20250930_lab.xml (EX-101.LAB) — 346KB
• fencf-20250930_pre.xml (EX-101.PRE) — 308KB
• fencf-20250930x10q_htm.xml (XML) — 1273KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION 3

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2025, and December 31, 2024 3 Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2025 and 2024 6 Notes to the Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 24

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 33

Controls and Procedures

Item 4. Controls and Procedures 33

: OTHER INFORMATION

PART II: OTHER INFORMATION 33

Legal Proceedings

Item 1. Legal Proceedings 33

Risk Factors

Item 1A. Risk Factors 35

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 35

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 35

Other Information

Item 5. Other Information 35

Exhibits

Item 6. Exhibits 35

Signatures

Signatures 37 Table of Contents PART 1: FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Fennec Pharmaceuticals Inc. Condensed Consolidated Balance Sheets (U.S. Dollars and shares in thousands) (Unaudited) September 30, December 31, 2025 2024 Assets Current assets Cash and cash equivalents $ 21,947 $ 26,634 Accounts receivable, net 19,343 12,884 Prepaid expenses 1,399 3,080 Inventory, net 2,477 1,060 Other current assets 898 466 Total current assets 46,064 44,124 Non-current assets Non-current accounts receivable, net 2,454 — Other non-current assets, net of amortization 743 822 Total non-current assets 3,197 822 Total assets $ 49,261 $ 44,946 Liabilities and stockholders' deficit Current liabilities: Accounts payable $ 5,866 $ 3,241 Accrued liabilities 3,701 3,428 Contract liability - current 248 248 Operating lease liability - current — 2 Total current liabilities 9,815 6,919 Long-term liabilities Term loan 18,206 18,206 PIK interest 1,271 1,271 Debt discount ( 100 ) ( 139 ) Contract liability - long-term 24,561 24,561 Total long-term liabilities 43,938 43,899 Total liabilities 53,753 50,818 Commitments and contingencies (Note 6) Stockholders' deficit: Common stock, no par value; unlimited shares authorized; 28,062 shares issued and outstanding (2024 27,527 ) 147,652 145,608 Additional paid-in capital 71,249 66,958 Accumulated deficit ( 224,636 ) ( 219,681 ) Accumulated other comprehensive income 1,243 1,243 Total stockholders' deficit ( 4,492 ) ( 5,872 ) Total liabilities and stockholders' deficit $ 49,261 $ 44,946 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents Fennec Pharmaceuticals Inc. Condensed Consolidated Statements of Operations (U.S. Dollars and shares in thousands, except per share amounts) (Unaudited) Three Months Ended Nine Months Ended Septe

View Full Filing

View this 10-Q filing on SEC EDGAR